See more : Beryl 8 Plus Public Company Limited (BE8.BK) Income Statement Analysis – Financial Results
Complete financial analysis of ACRES Commercial Realty Corp. (ACR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACRES Commercial Realty Corp., a leading company in the REIT – Mortgage industry within the Real Estate sector.
You may be interested
- Syarikat Takaful Malaysia Keluarga Berhad (6139.KL) Income Statement Analysis – Financial Results
- CleanGo Innovations Inc. (CGII.CN) Income Statement Analysis – Financial Results
- Brooks Laboratories Limited (BROOKS.NS) Income Statement Analysis – Financial Results
- Decisionpoint Systems, Inc. (DPSIP) Income Statement Analysis – Financial Results
- Analogue Holdings Limited (1977.HK) Income Statement Analysis – Financial Results
ACRES Commercial Realty Corp. (ACR)
About ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp., a real estate investment trust (REIT), focuses on the origination, holding, and management of commercial real estate mortgage loans and other commercial real estate-related debt investments in the United States. It invests in commercial real estate-related assets, including floating and fixed rate first mortgage loans, first priority interests in first mortgage loans, subordinated interests in first mortgage loans, mezzanine debt, preferred equity investments, commercial mortgage-backed securities, and commercial real estate equity and preferred equity investments. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income tax to the extent that it distributes 100% of its REIT taxable income. The company was formerly known as Exantas Capital Corp. and changed its name to ACRES Commercial Realty Corp. in February 2021. ACRES Commercial Realty Corp. was incorporated in 2005 and is based in Uniondale, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 80.23M | 70.01M | 44.86M | 19.49M | 47.52M | 36.62M | 45.96M | 29.75M | 123.92M | 112.30M | 91.59M | 107.72M | 95.98M | 85.33M | 52.71M | 53.20M | 54.79M | 26.75M | 18.64M |
| Cost of Revenue | 38.91M | 33.85M | 6.18M | 298.00K | 9.00M | 11.33M | 13.26M | 9.00K | 57.00K | 5.44M | 14.06M | 4.70M | 0.00 | 0.00 | 0.00 | 2.91M | 2.91M | 1.88M | 0.00 |
| Gross Profit | 41.32M | 36.15M | 38.68M | 19.19M | 38.52M | 25.29M | 32.71M | 29.74M | 123.86M | 106.86M | 77.53M | 103.02M | 95.98M | 85.33M | 52.71M | 50.29M | 51.88M | 24.87M | 18.64M |
| Gross Profit Ratio | 51.50% | 51.64% | 86.22% | 98.47% | 81.06% | 69.06% | 71.16% | 99.97% | 99.95% | 95.15% | 84.65% | 95.64% | 100.00% | 100.00% | 100.00% | 94.53% | 94.69% | 92.97% | 100.00% |
| Research & Development | 0.00 | 0.07 | 0.32 | 2.45 | 0.25 | 0.22 | 0.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 17.97M | 7.80M | 6.33M | 9.56M | 12.60M | 13.38M | 18.58M | 18.23M | 51.29M | 46.87M | 40.64M | 17.76M | 21.95M | 22.88M | 16.06M | 1.85M | 1.58M | 1.50M | 3.81M |
| Selling & Marketing | 2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.55M | 7.80M | 6.33M | 9.56M | 12.60M | 13.38M | 18.58M | 18.23M | 51.29M | 46.87M | 40.64M | 17.76M | 21.95M | 22.88M | 16.06M | 1.85M | 1.58M | 1.50M | 3.81M |
| Other Expenses | 0.00 | 1.59M | 822.00K | 471.00K | 1.41M | 2.00M | -579.00K | 1.50M | 60.00K | -1.26M | 391.00K | 19.20M | 3.02M | -7.81M | -44.55M | 8.92M | 8.92M | 0.00 | -11.53M |
| Operating Expenses | 31.55M | 9.39M | 7.16M | 10.03M | 14.01M | 11.14M | 33.79M | 77.01M | 48.08M | 15.26M | 16.11M | 4.43M | 24.97M | 16.06M | 12.44M | 10.50M | 10.50M | 1.50M | -7.73M |
| Cost & Expenses | 70.46M | 67.41M | 7.16M | 10.03M | 14.01M | 11.14M | 33.79M | 77.02M | 48.14M | 15.26M | 16.11M | 9.13M | 24.97M | 16.06M | 12.44M | 13.42M | 13.42M | 3.38M | -7.73M |
| Interest Income | 187.47M | 126.27M | 101.03M | 108.24M | 144.89M | 122.78M | 99.32M | 112.62M | 158.08M | 126.91M | 117.98M | 133.33M | 110.19M | 103.91M | 97.59M | 134.34M | 177.00M | 136.75M | 61.39M |
| Interest Expense | 130.79M | 82.32M | 61.58M | 58.01M | 83.84M | 67.62M | 57.66M | 53.75M | 65.65M | 45.47M | 61.01M | 42.79M | 30.43M | 36.47M | 45.43M | 79.62M | 121.56M | 101.85M | 43.06M |
| Depreciation & Amortization | 91.00K | 65.11M | 4.60M | 62.46M | 110.04M | 30.29M | 92.97M | 104.42M | 4.86M | 2.74M | 3.86M | 5.89M | 4.62M | 4.00M | 1.36M | 3.38M | 4.09M | 3.73M | 2.81M |
| EBITDA | 149.96M | 88.44M | 0.00 | -136.79M | 38.21M | 93.21M | 89.82M | 13.73M | 0.00 | 0.00 | -10.51M | 68.62M | 69.47M | 0.00 | -22.03M | 0.00 | 0.00 | 19.34M | 13.72M |
| EBITDA Ratio | 186.92% | 143.67% | 106.79% | -981.16% | 75.79% | 266.58% | 219.64% | 60.23% | 59.08% | 95.47% | 120.47% | 118.57% | 75.81% | 71.24% | 100.78% | 149.79% | 246.16% | 453.05% | 304.70% |
| Operating Income | 20.67M | 93.09M | 33.92M | -197.71M | 35.97M | 94.70M | 47.46M | -14.34M | 18.93M | 62.17M | 46.45M | 45.25M | 68.15M | 17.21M | 19.81M | -3.32M | 9.23M | 15.61M | 10.91M |
| Operating Income Ratio | 25.77% | 132.97% | 75.61% | -1,014.64% | 75.69% | 258.64% | 103.25% | -48.22% | 15.27% | 55.36% | 50.72% | 42.01% | 71.00% | 20.17% | 37.58% | -6.23% | 16.84% | 58.34% | 58.53% |
| Total Other Income/Expenses | 1.27M | 2.91M | 0.00 | -54.40M | -3.32M | -5.28M | 6.61M | 14.00M | -41.43M | 13.04M | 23.43M | 33.82M | -16.66M | 27.93M | -29.77M | -45.60M | -32.79M | 0.00 | 0.00 |
| Income Before Tax | 21.95M | 10.76M | 33.92M | -197.71M | 36.22M | 26.96M | 54.07M | -342.00K | 18.93M | 59.96M | 45.41M | 79.05M | 52.82M | 6.34M | 6.34M | -3.32M | 9.23M | 15.61M | 0.00 |
| Income Before Tax Ratio | 27.35% | 15.37% | 75.61% | -1,014.64% | 76.22% | 73.64% | 117.64% | -1.15% | 15.27% | 53.39% | 49.58% | 73.38% | 55.03% | 7.43% | 12.02% | -6.23% | 16.84% | 58.34% | 0.00% |
| Income Tax Expense | 97.00K | 336.00K | -42.40M | -84.21M | 251.00K | -343.00K | 6.61M | 10.99M | 1.75M | -2.21M | -1.04M | 14.60M | 15.10M | 26.47M | -2.00K | -241.00K | 338.00K | 128.98M | 43.06M |
| Net Income | 22.39M | 10.62M | 33.92M | -197.71M | 35.97M | 27.43M | 33.54M | -30.37M | 10.56M | 61.20M | 46.45M | 64.44M | 37.72M | 19.45M | 6.34M | -3.07M | 8.89M | 15.61M | 10.91M |
| Net Income Ratio | 27.91% | 15.17% | 75.61% | -1,014.64% | 75.69% | 74.91% | 72.96% | -102.08% | 8.52% | 54.50% | 50.72% | 59.83% | 39.30% | 22.79% | 12.03% | -5.78% | 16.22% | 58.34% | 58.53% |
| EPS | 0.35 | -1.00 | 1.85 | -18.37 | 2.44 | 2.64 | 0.54 | -2.98 | -1.29 | 4.14 | 3.96 | 8.52 | 6.48 | 4.92 | 3.00 | -1.49 | 4.32 | 10.68 | 8.52 |
| EPS Diluted | 0.35 | -1.00 | 1.85 | -18.37 | 2.43 | 2.62 | 0.54 | -2.98 | -1.29 | 4.08 | 3.93 | 8.52 | 6.36 | 4.92 | 3.00 | -1.49 | 4.32 | 10.44 | 8.52 |
| Weighted Avg Shares Out | 8.42M | 8.81M | 9.74M | 10.76M | 10.48M | 10.40M | 10.28M | 10.18M | 10.75M | 10.67M | 9.87M | 7.37M | 5.87M | 3.98M | 2.10M | 2.06M | 2.05M | 1.46M | 1.28M |
| Weighted Avg Shares Out (Dil) | 8.57M | 8.81M | 9.76M | 10.76M | 10.56M | 10.46M | 10.36M | 10.18M | 10.76M | 10.77M | 10.00M | 7.44M | 5.90M | 3.99M | 2.11M | 2.06M | 2.07M | 1.49M | 1.28M |
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO , Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at...
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced preclinical data for ALLO-329,...
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition...
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1...
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed EMERYVILLE, Calif. ,...
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer...
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session Results from the Phase 2 DAHLIAS study...
Source: https://incomestatements.info
Category: Stock Reports